Madrigal Pharmaceuticals
Madrigal is focused on developing therapeutics to improve the lives of patients with metabolic and fatty liver diseases.
Madrigal is focused on developing therapeutics to improve the lives of patients with metabolic and fatty liver diseases.
Madrigal Pharmaceuticals is a biopharmaceutical company founded in 2016, focusing on developing therapeutics for metabolic and fatty liver diseases. The company's first therapy received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis and is currently undergoing a Phase 3 trial for the treatment of NASH with compensated cirrhosis. Madrigal Pharmaceuticals operates in the biopharma, biotechnology, medical devices, and pharmaceutical industries. The company's recent Post-IPO Equity investment on 18th March 2024 marks a significant milestone in its financial journey.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | Unknown | - | 18 Mar 2024 | |
| Post-IPO Equity | Unknown | - | 28 Sep 2023 | |
| Post-IPO Equity | Unknown | - | 21 Dec 2022 | |
| Post-IPO Debt | Unknown | - | 09 May 2022 | |
| Post-IPO Equity | Unknown | - | 05 Nov 2020 |
No recent news or press coverage available for Madrigal Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
